17 citations
,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
16 citations
,
July 2017 in “Rheumatology and Therapy” Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
16 citations
,
January 2017 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” A patient with complete hair loss regrew all her hair using tofacitinib.
15 citations
,
November 2020 in “Pharmaceutics” Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
11 citations
,
November 2019 in “Clinical Case Reports” A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
11 citations
,
November 2018 in “Journal of the American Academy of Dermatology” Tofacitinib therapy can effectively regrow eyebrows and eyelashes in some alopecia areata patients.
9 citations
,
May 2021 in “International Journal of Dermatology” The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
9 citations
,
April 2018 in “Journal of Dermatological Treatment” Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.
2 citations
,
October 2018 in “Archives of Dermatological Research” Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.
1 citations
,
January 2023 in “Research Square (Research Square)” A woman's vitiligo improved with tofacitinib treatment, and her skin color remained even after stopping the medication, but there are concerns about cancer risk.
1 citations
,
October 2020 in “Journal of Cosmetic Dermatology” Using minoxidil and tofacitinib together can effectively treat severe hair loss.
March 2026 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
June 2025 in “International Journal of Science and Research (IJSR)” Tofacitinib effectively promotes hair regrowth in alopecia areata with minimal side effects.
January 2025 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib improved hair regrowth and quality of life in children with alopecia areata, with mild side effects.
March 2024 in “Clinical, cosmetic and investigational dermatology” Tofacitinib successfully treated vitiligo in a patient with lupus without side effects.
June 2020 in “Journal of Investigative Dermatology” Getting insurance to cover the hair loss treatment tofacitinib is hard because it's not officially approved for that use.
11 citations
,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
13 citations
,
February 2017 in “Clinical rheumatology” Tofacitinib may help treat nail dystrophy, especially when other treatments fail.
11 citations
,
January 2020 in “Dermatologica Sinica” Tofacitinib helps regrow hair in severe alopecia patients, but more research is needed.
8 citations
,
January 2017 in “Dermatology online journal” Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
June 2024 in “Indian Dermatology Online Journal” Topical tofacitinib is effective and safe for treating alopecia areata.
159 citations
,
October 2015 in “Science Advances” Blocking JAK-STAT signaling can lead to hair growth.
124 citations
,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
77 citations
,
June 2017 in “Advances in Therapy” New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
55 citations
,
October 2019 in “Dermatology and therapy” Drugs targeting the JAK/STAT pathway can improve atopic dermatitis but vary in effectiveness for vitiligo and alopecia areata, with generally mild safety concerns.
49 citations
,
August 2018 in “International Journal of Dermatology” Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.
40 citations
,
December 2016 in “Journal of Dermatological Treatment” JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.